Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 70.6 NOK -1.81% Market Closed
Market Cap: 1.9B NOK

Photocure ASA
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Photocure ASA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Photocure ASA
OSE:PHO
Operating Income
kr877k
CAGR 3-Years
N/A
CAGR 5-Years
-52%
CAGR 10-Years
-16%
V
Vistin Pharma ASA
OSE:VISTN
Operating Income
kr97.4m
CAGR 3-Years
N/A
CAGR 5-Years
19%
CAGR 10-Years
N/A
N
Navamedic ASA
OSE:NAVA
Operating Income
kr21.1m
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
13%
S
SoftOx Solutions AS
OSE:SOFTX
Operating Income
-kr19.9m
CAGR 3-Years
39%
CAGR 5-Years
8%
CAGR 10-Years
N/A
O
Oncoinvent ASA
OSE:ONCIN
Operating Income
-kr115.3m
CAGR 3-Years
28%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

Photocure ASA
Glance View

Market Cap
1.9B NOK
Industry
Pharmaceuticals

Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

PHO Intrinsic Value
85.56 NOK
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Photocure ASA's Operating Income?
Operating Income
877k NOK

Based on the financial report for Jun 30, 2025, Photocure ASA's Operating Income amounts to 877k NOK.

What is Photocure ASA's Operating Income growth rate?
Operating Income CAGR 10Y
-16%

Over the last year, the Operating Income growth was -98%.

Back to Top